Vivani expects to initiate the first clinical study supporting the NPM-115 program in the fourth quarter of 2024 The NPM-115 clinical program...
NPM-119 is being studied to address medication non-adherence and potentially improve tolerability issues associated with oral and injectable type...
Data Published in BMC Veterinary Research shows that OKV-119 exenatide implant reduced feline weight Felines share many pathophysiologic obesity...
Company continues advancing the development of miniature, long-term GLP-1 implants for the treatment of chronic weight management in obese or...
Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.